Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07099742 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 5 months later Apr 2026 → Oct 2027
See other at-risk trials from Dr. Md. Alimur Reza

Record History

  1. Primary completion pushed from Apr 2026 to Oct 2027 Start date: Sep 2025 to Nov 2026 · Completion pushed from Jul 2026 to Dec 2027 · Eligibility criteria expanded, about 13 words · 2 more Show 5 more changesShow less
    • Start date: Sep 2025 to Nov 2026
    • Completion pushed from Jul 2026 to Dec 2027
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 2 of 9 entries
    • Publications: details revised at 4 of 4 entries
  2. Site contacts updated at 3 of 3 sites Publications reorderedv2 Show 1 more changeShow less
    • Publications reordered
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Dr. Md. Alimur Reza
3 trials monitored
See 1 trial at risk
Obesity
3,560 trials monitored
See 142 trials at risk
This is a prospective, multicenter, real-world study conducted in Bangladesh to assess the effectiveness and safety of Tirzepatide compared to structured lifestyle interventions, including dietary modifications and exercise, in obese adults with or without Type 2 Diabetes Mellitus (T2DM). The study aims to determine whether treatment with Tirzepatide results in superior weight reduction outcomes compared to lifestyle-based approaches. Adult participants (≥18 years) with a body mass index (BMI) ≥25 kg/m² and no prior exposure to GLP-1 receptor agonists will be enrolled at the discretion of the treating physician. Eligible participants will receive either once-weekly Tirzepatide or participate in lifestyle intervention programs aligned with standard clinical care.
Trial Details
NCT Number NCT07099742
Lead Sponsor Dr. Md. Alimur Reza
Conditions Obesity
Enrollment 364 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov